B2M and colorectal cancer: The biallelic loss of B2M (frameshift deletion/loss of heterozygosity) leads to impaired antigen presentation, which may contribute to intrinsic resistance to immune checkpoint blockade therapy in dMMR/MSI-H colorectal cancer. Furthermore, NK cell-based immunotherapies, particularly those involving the adoptive transfer of “educated” NK cells, represent a promising alternative therapeutic strategy.